Table 1. Patient characteristics.
| Healthy (n = 8) | AKI-free (n = 11) | AKI (n = 20) | P value | |
| Age (years) | 33.6±11.2 | 43.6±10.0 | 48.7±14.0 | 0.026 |
| Sex (male/female) | 8/0 | 4/7 | 8/12 | |
| Body weight (kg) | 65.1±9.8 | 61.0±12.4 | 54.7±10.2 | NS |
| Primary disease (n) | ||||
| Biliary atresia | 2 | 2 | ||
| Primary biliary cirrhosis | 1 | 6 | ||
| Hepatitis C virus-related liver cancer | 1 | 5 | ||
| Other | 7 | 7 | ||
| ABO blood group match | ||||
| Identical | 6 | 14 | ||
| Compatible | 2 | 2 | ||
| Incompatible | 3 | 4 | ||
| Child Pugh score | - | 8.5±2.3 | 10.5±2.2 | 0.037 |
| MELD score | - | 15.0±6.9 | 18.3±5.2 | NS |
| Donor (Living/Cadaveric), n | - | 10/1 | 18/2 | |
| Preoperative Scr (mg/dL) | 0.78±0.06 | 0.61±0.19 | 0.69±0.24 | 0.024 |
| Preoperative BUN (mg/dL) | 12.6±4.8 | 13.6±5.8 | 17.1±7.0 | NS |
| Preoperative eGFR(mL/minute/1.73 m2) | 94.9±9.4 | 96.8±28.0 | 86.6±26.7 | NS |
| Total dose of tacrolimus betweenPOD 1 and 21 (mg) | - | 67.8±41.5 | 58.5±35.3 | NS |
| Mean blood levels of tacrolimus during the 21-day postoperative period(ng/mL) | - | 8.65±1.97 | 8.51±1.79 | NS |
NOTE: The results are given as mean ± standard deviation. Statistical analysis was performed using the Mann-Whitney U test and Kruskal-Wallis test.
Abbreviations: BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; MELD, Model for End-stage Liver Disease; Scr, serum creatinine; POD, postoperative day.